Russia discussing the possibility of producing generic Sovaldi with Gilead
The Russian Ministry of Health plans to initiate talks with US biotech major Gilead Sciences (Nasdaq: GILD) on beginning production of generic versions of its sofosbuvir, marketed as Sovaldi, which is a drug for the treatment of hepatitis C, that was included in the list of vital and essential medicines in Russia for 2019, reports The Pharma Letter’s local correspondent.
Currently sofosbuvir remains one of the most efficient and probably most expensive drug for the treatment of hepatitis, available in the Russian market. According to the Russian Ministry of Health, the average cost of one 12-week course is more than 705,000 roubles ($10,368).
The proposed price of the drug does not fit into the state budget, which forces the Russian government to consider the possibility of establishing producing generics of the drug in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze